Cognitive-behavioral therapy for the improvement of negative symptoms and functioning in schizophrenia: A systematic review and meta-analysis of randomized controlled trials

PLoS ONE, Год журнала: 2025, Номер 20(5), С. e0324685 - e0324685

Опубликована: Май 20, 2025

Background Negative symptoms of schizophrenia are a range deficits or losses in mental functioning associated with the disorder, including blunted affect, alogia, avolition, asociality, and anhedonia. These severely impact quality life patients hinder recovery process. They significantly impair patients’ ability to live independently, maintain social relationships, function effectively society. However, current treatments for negative limited efficacy remain controversial. Cognitive-behavioral therapy (CBT) is goal-oriented psychotherapy that aims improve individuals’ emotional psychological states by changing their thought patterns behaviors. It helps identify challenge irrational beliefs while promoting more positive behavioral changes through experiments skills training. This study conduct meta-analysis assess effects CBT on schizophrenia. Objectives aimed investigate cognitive symptoms, function, skills, Methods Literature was retrieved from 10 databases (PubMed, EMBASE, Cochrane Library, Web Science, APA PsycINFO, CINAHL, MEDLINE, CNKI, Wan fang Database SinoMed,), search period ranging inception date 1 September 2024. Two researchers independently conducted literature review, data extraction, risk bias assessment. The included studies assessed using Risk Bias tool, RevMan 5.3. measurement outcomes include schizophrenia, overall functioning. Result analysis total 15 involving 1,311 participants. All used Positive Syndrome Scale (PANSS) as assessment tool measuring results indicated cognitive-behavioral improved compared treatment usual (TAU) (MD = -1.65, 95% CI -2.10 -1.21, p < 0.001, I² 41%). Short-term -2.71, -3.18 -1.61, 48%). Medium-term also -1.80, -2.76 -0.84, 29%). Long-term demonstrated significant improvement well -1.70, -2.54 -0.85, 0%). (SMD 0.38, 0.13 0.63, 0.05, Additionally, enhanced 0.87, 0.58 1.16, 0%) 0.19, 0.03 0.36, 24%) these patients. Conclusion indicate has effect improving markedly superior Treatment Usual (TAU). Moreover, all three sub-treatment approaches (short-term, medium-term, long-term) can sustainably Future research should focus developing evaluating therapies targeting providing reliable evidence applying findings clinical practice.

Язык: Английский

Targeting Neuroinflammation in Schizophrenia: A comprehensive review of mechanisms and pharmacological interventions

International Immunopharmacology, Год журнала: 2025, Номер 159, С. 114910 - 114910

Опубликована: Май 26, 2025

Язык: Английский